Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT05230901
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- University Medical Center Goettingen
- Registry
-
NCT05230901
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Unknown status
Technical summary
Registry record NCT05230901. Randomized; no masking; primary purpose treatment. Start 2022-02-23 (actual); primary completion 2025-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
- Acronym
- Reduce-MFA
- Condition
- Aortic Stenosis, Severe
- Intervention (Other)
- Standard of Care
- Intervention (Drug)
- Spironolactone 25mg
- Intervention (Drug)
- Dihydralazine
- Lead sponsor
- University Medical Center Goettingen
Record details
- Record id
cardio:ct-nct05230901- Content hash
3a9ae49d55ef33d8b3efe060034a5e3f6d115b81f9738381099a22bde6a9dbdc